Published Date: 14 Aug 2025
A study from Denmark shows for the first time that men with biochemically recurrent prostate cancer who undergo PSMA PET/CT before salvage radiotherapy have improved survival rates compared to those who do not.
Read Full NewsIn patients with newly diagnosed fibromyalgia who have prominent symptoms of anxiety and depression, remission of depression — not pain reduction alone — determines clinical improvement.
Most ADHD coaches do not have behavioral health training, a study finds, but experts say peer support can help people navigate living with the condition.
In the long term, stereotactic body radiotherapy carries a lower risk for biochemical failure vs high-dose rate brachytherapy for men with intermediate-risk prostate cancer.
1.
Access to GLP-1 medications associated with a lower risk of colorectal cancer in people with type 2 diabetes: JAMA.
2.
Efanesoctocog Alfa Prevented Bleeding in Kids With Severe Hemophilia A
3.
Interleukin-6 may boost prediction of obesity-related cancers
4.
Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.
5.
Compared to previous estimates, a greater number of patients participate in cancer treatment trials.
1.
Understanding Neutropenic Fever: What It Is and Why it's a Serious Concern
2.
Role of Type I Interferons and KDM1B in Driving Cancer Stemness and Therapeutic Evasion
3.
Transfusing the Future: Exploring the Possibilities of Blood Transfusions
4.
Unveiling the Hidden Causes of Anemia: A Comprehensive Look at a Common Condition
5.
Unleashing the Power of Immune Triads: A Novel Approach to Cancer Immunotherapy
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III
3.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation